National data from 2022 to 2023 estimated that for every 1,000 patients prescribed semaglutide, there were less than four emergency department (ED) visits, mainly for gastrointestinal symptoms.

The diabetes program could renew its focus on investigating this with its 1,700 aging participants. The group added a new principal investigator, the dementia expert Dr. Jose A. Luchsinger.